Cargando…

Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?

Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with unsatisfactory treatment options. Best management and recruitment into clinical trials requires early diagnosis. However, diagnosis is often delayed. Analysis of the diagnostic pathway and identification...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falcão de Campos, Catarina, Gromicho, Marta, Uysal, Hilmi, Grosskreutz, Julian, Kuzma-Kozakiewicz, Magdalena, Oliveira Santos, Miguel, Pinto, Susana, Petri, Susanne, Swash, Michael, de Carvalho, Mamede
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596501/ https://www.ncbi.nlm.nih.gov/pubmed/34803894 http://dx.doi.org/10.3389/fneur.2021.761355

Ejemplares similares

Trends in the diagnostic delay and pathway for amyotrophic lateral sclerosis patients across different countries
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

Spreading in ALS: The relative impact of upper and lower motor neuron involvement
por: Gromicho, Marta, et al.
Publicado: (2020)

Analysis of routine blood parameters in patients with amyotrophic lateral sclerosis and evaluation of a possible correlation with disease progression—a multicenter study
por: Hertel, Nora, et al.
Publicado: (2022)

Emotional Lability at Disease Onset Is an Independent Prognostic Factor of Faster Disease Progression in Amyotrophic Lateral Sclerosis
por: Barć, Krzysztof, et al.
Publicado: (2020)

Diaphragmatic Neurophysiology and Respiratory Markers in ALS
por: de Carvalho, Mamede, et al.
Publicado: (2019)

Influence of Environment and Lifestyle on Incidence and Progress of Amyotrophic Lateral Sclerosis in A German ALS Population
por: Korner, Sonja, et al.
Publicado: (2019)

Potential Preventive Strategies for Amyotrophic Lateral Sclerosis
por: Kuraszkiewicz, B., et al.
Publicado: (2020)

SVC Is a Marker of Respiratory Decline Function, Similar to FVC, in Patients With ALS
por: Pinto, Susana, et al.
Publicado: (2019)

MRSA in Humans, Pets and Livestock in Portugal: Where We Came from and Where We Are Going
por: Silva, Vanessa, et al.
Publicado: (2022)

Pathologic expansion in the C9orf72 gene is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis
por: Miltenberger-Miltenyi, Gabriel, et al.
Publicado: (2021)

Where We Mentalize: Main Cortical Areas Involved in Mentalization
por: Monticelli, Matteo, et al.
Publicado: (2021)

Chronic Traumatic Encephalopathy in Professional American Football Players: Where Are We Now?
por: Tharmaratnam, Tharmegan, et al.
Publicado: (2018)

The future of high-grade glioma: Where we are and where are we going
por: Rhun, Emilie Le, et al.
Publicado: (2015)

Investigating LGALS3BP/90 K glycoprotein in the cerebrospinal fluid of patients with neurological diseases
por: Costa, Júlia, et al.
Publicado: (2020)

The Challenging Path to Developing a Mobile Health Device for Epilepsy: The Current Landscape and Where We Go From Here
por: Hubbard, Ilona, et al.
Publicado: (2021)

Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
por: Cova, Ilaria, et al.
Publicado: (2018)

Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
por: Hilmi, Marc, et al.
Publicado: (2018)

Geriatric Oncology in Portugal: Where We Are and What Comes Next—A Survey of Healthcare Professionals
por: Marinho, Joana, et al.
Publicado: (2022)

Motoneuron firing in amyotrophic lateral sclerosis (ALS)
por: de Carvalho, Mamede, et al.
Publicado: (2014)

Dermatology: Where are We Coming from and Where are We Going to?
por: van de Kerkhof, Peter C. M.
Publicado: (2014)

Mesenchymal Stromal Cells’ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?
por: Barros, Inês, et al.
Publicado: (2020)

Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease
por: Prell, Tino, et al.
Publicado: (2019)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

γ' Fibrinogen as a Predictor of Survival in Amyotrophic Lateral Sclerosis
por: Pronto-Laborinho, Ana Catarina, et al.
Publicado: (2021)

Corrigendum: γ′ Fibrinogen as a Predictor of Survival in Amyotrophic Lateral Sclerosis
por: Pronto-Laborinho, Ana Catarina, et al.
Publicado: (2021)

The Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis: Signals From the CNS and Beyond
por: Gaur, Nayana, et al.
Publicado: (2020)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Update on cervical disc arthroplasty: where are we and where are we going?
por: Jaramillo-de la Torre, Jorge J., et al.
Publicado: (2008)

Mitochondrial Neurogastrointestinal Encephalomyopathy: Novel Pathogenic Mutation in Thymidine Phosphorylase Gene in a Patient from Cape Verde Islands
por: Falcão de Campos, Catarina, et al.
Publicado: (2019)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

Francisella tularensis, Portugal
por: Lopes de Carvalho, Isabel, et al.
Publicado: (2007)

Sporadic Spinal-Onset Amyotrophic Lateral Sclerosis Associated with Myopathy in Three Unrelated Portuguese Patients
por: Oliveira Santos, Miguel, et al.
Publicado: (2023)

THREE-DIMENSIONAL PRINTING IN ORTHOPEDICS: WHERE WE STAND AND WHERE WE ARE HEADING
por: EJNISMAN, LEANDRO, et al.
Publicado: (2021)

Computational methods applied to syphilis: where are we, and where are we going?
por: Albuquerque, Gabriela, et al.
Publicado: (2023)

Tuberculosis: where are we?
por: Mello, Fernanda Carvalho de Queiroz, et al.
Publicado: (2018)

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
por: Lingor, Paul, et al.
Publicado: (2019)

Roles of Vascular Endothelial Growth Factor in Amyotrophic Lateral Sclerosis
por: Pronto-Laborinho, Ana Catarina, et al.
Publicado: (2014)

Developing a Neuroimaging Biomarker for Amyotrophic Lateral Sclerosis: Multi-Center Data Sharing and the Road to a “Global Cohort”
por: Steinbach, Robert, et al.
Publicado: (2018)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

TSACO’s Third Anniversary: where we were, where we are, and where we’re going
por: Fabian, Timothy
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_riu2nthj0qmg7vf4u2kou0353p